EXM-42342-43058
2 vaccinations
1 coded response
1 check-in
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 201 / VA
- Registered
- 2021-04-28
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-30
Dose 1 — Pfizer-BioNTech
-
2021-04-27
Dose 2 — Pfizer-BioNTech
-
2021-04-28
Registered in v-safe
-
2021-04-28
Survey response — days 1–6 daily, dose 2MedDRA: Rhinorrhoea, Sneezing — Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tirednessFree text: Running nose and sneezingMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-30 | Pfizer-BioNTech | |
| 2 | 2021-04-27 | Pfizer-BioNTech |
Free text
Release 8 — days 1–6 daily, dose 2
Systemic reaction (other): Running nose and sneezing
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Rhinorrhoea | ✓ | ✓ | ✓ |
| SRO | Sneezing | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release